Today: 29 April 2026
Browse Category

ASX:MSB 3 October 2025 - 6 March 2026

Mesoblast Limited shares rise as Ryoncil launch puts $120 million sales target in play

Mesoblast Limited shares rise as Ryoncil launch puts $120 million sales target in play

Mesoblast shares rose 3% in early U.S. trading Friday after the company reported first-half revenue of $51.3 million, up from $3.2 million a year earlier, driven by Ryoncil sales. The company set a fiscal 2026 net revenue target of $110–$120 million for Ryoncil and said 49 transplant centers have been onboarded. Cash stood at $130 million as of Dec. 31. An adult trial for Ryoncil is expected to begin after ethics approval in March.
6 March 2026
·
Australia stock market today: ASX 200 closes higher as tech rebounds; BlueScope pushes back on $13.2b bid

Australia stock market today: ASX 200 closes higher as tech rebounds; BlueScope pushes back on $13.2b bid

The S&P/ASX 200 closed up 0.29% at 8,720.8, led by gains in tech and healthcare, while miners fell. BlueScope rejected a A$13.2 billion takeover bid from SGH and Steel Dynamics. Ansell shares dropped 6.2% as CEO Neil Salmon announced his retirement, with Nathalie Ahlström set to take over in February. The Australian dollar slipped to about 67 U.S. cents.
8 January 2026
·········
Australian Stock Market Today: ASX 200 Climbs 0.8% as Takeover Deals, CPI Shock and Retail Rout Shape 26 November 2025

Australian Stock Market Today: ASX 200 Climbs 0.8% as Takeover Deals, CPI Shock and Retail Rout Shape 26 November 2025

The S&P/ASX 200 rose 0.81% to 8,606.5 Wednesday, shrugging off a jump in annual inflation to 3.8%. Temple & Webster plunged 32% after weak revenue growth, while National Storage REIT surged nearly 20% on a $4 billion takeover bid. The Australian dollar climbed to US$0.6505. Miners and healthcare stocks led gains.
26 November 2025
·········
Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast shares closed at $17.02 on Oct. 2, up 4.6% after the FDA-approved Ryoncil won permanent CMS reimbursement via a new J-code. The company confirmed its cell therapies are made from U.S. donors and not subject to tariffs. Wall Street consensus is “Buy” with a $24 average price target. Hedge funds have increased stakes, but overall institutional ownership remains low.
3 October 2025
··

Stock Market Today

  • Aurelia Metals and Top ASX Penny Stocks Highlighted Amid Market Downturn
    April 28, 2026, 11:58 PM EDT. The Australian share market faces a seventh day of decline amid inflation and interest rate concerns. Investors are eyeing ASX penny stocks for growth opportunities, including Aurelia Metals Limited (ASX:AMI), valued at A$474.15 million with earnings growth of 275.5% over the past year. Aurelia's financials show strong short-term assets and healthy cash flow covering debt, trading below estimated fair value. Other notable penny stocks include Nova Eye Medical and LaserBond. Caution is advised as some boards lack seasoned leadership. Despite overall market weakness, certain penny stocks offer potential value for risk-tolerant investors.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop